UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel breast cancer treatment leads to hyperglycaemia

Diabetic medicine, 2020-05, Vol.37 (5), p.893-894

2020

Volltextzugriff (PDF)

Ethnic Neutropenia and Treatment Delay in African American Women Undergoing Chemotherapy for Early-Stage Breast Cancer

JNCI : Journal of the National Cancer Institute, 2003-10, Vol.95 (20), p.1545-1548

2003

Volltextzugriff (PDF)

Novel Combination of Toll-Like Receptor (TLR)-7 Agonist Imiquimod and Local Radiation Therapy in the Treatment of Metastatic Breast Cancer Involving the Skin or Chest Wall

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S111-S111

2013

Volltextzugriff (PDF)

Combination of irinotecan and bevacizumab for heavily pretreated recur- rent ovarian cancer: A phase II trial

Gynecologic oncology, 2013-07, Vol.130 (1), p.e12-e12

2013

Volltextzugriff (PDF)

Minimal Acute Toxicity Associated With Concurrent Adjuvant Carboplatin and Accelerated Radiation Therapy for Triple Negative Breast Cancer

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S251-S251

2012

Volltextzugriff (PDF)

Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers

Gynecologic oncology, 2012-03, Vol.125, p.S22-S22

2012

Volltextzugriff (PDF)

PP 66 Utility of VEGF and IL-6 as biomarkers for response to PTC299, a novel antiangiogenic

European journal of cancer (1990), 2011, Vol.47, p.S15-S15

2011

Volltextzugriff (PDF)

CA-125 surveillance for women with ovarian, fallopian tube or primary peritoneal cancers: What do survivors think?

Gynecologic oncology, 2011-03, Vol.120, p.S64-S64

2011

Volltextzugriff (PDF)

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

Journal of clinical oncology, 1995-10, Vol.13 (10), p.2575-2581

1995

Volltextzugriff (PDF)

Abstract P5-11-07: The significance of androgen receptor co-expression in ER+ metastatic breast cancer patients treated with palbociclib

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-11-07

2019

Volltextzugriff (PDF)

Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy

Journal of clinical oncology, 1996-07, Vol.14 (7), p.2043-2046

1996

Volltextzugriff (PDF)

Abstract P1-07-28: Retrospective analysis of clinicopathologic features predictive of oncotype DX discordance in estrogen receptor positive, node negative breast cancer patients

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-28

2018

Volltextzugriff (PDF)

Abstract OT1-03-08: A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT1-03-08-OT1-03-08

2018

Volltextzugriff (PDF)

Abstract P1-07-16: Retrospective analysis of oncotype DX recurrence score (RS) and discordance in patients with node-negative, ER+ breast cancer with recurrence

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-07-16

2018

Volltextzugriff (PDF)

Abstract OT1-01-10: Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-01-10-OT1-01-10

2017

Volltextzugriff (PDF)

Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-05-09-OT3-05-09

2018

Volltextzugriff (PDF)

Phase I/II study of tandem cycles of high‐dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer

International journal of gynecological cancer, 2006-01, Vol.16 (1), p.57-64

2006

Volltextzugriff (PDF)

Abstract OT2-01-19: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-19-OT2-01-19

2017

Volltextzugriff (PDF)

Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer

International journal of gynecological cancer, 2006, Vol.16 (1), p.57-64

2006

Volltextzugriff (PDF)

Complementary and alternative medicine : The role of the cancer center

Journal of clinical oncology, 2001-09, Vol.19 (18), p.55s-60s

2001

Volltextzugriff (PDF)

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

Annals of oncology, 2008-07, Vol.19 (7), p.1231-1241

2008

Volltextzugriff (PDF)

High-dose chemotherapy for breast cancer: evolving data

Oncology (Williston Park, N.Y.), 1999-09, Vol.13 (9), p.1215-1219

1999

Volltextzugriff (PDF)

Reduction of Paclitaxel-induced Peripheral Neuropathy with Glutamine

Clinical cancer research, 2001-05, Vol.7 (5), p.1192-1197

2001

Volltextzugriff (PDF)

Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer

Bone marrow transplantation (Basingstoke), 2002-08, Vol.30 (3), p.149-155

2002

Volltextzugriff (PDF)

Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer

Clinical cancer research, 1998-07, Vol.4 (7), p.1689-1695

1998

Volltextzugriff (PDF)

1 – 25 von 574

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(331)
Mit Volltextzugriff
(405)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(573)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Novel breast cancer treatment leads to hyperglycaemia

Ethnic Neutropenia and Treatment Delay in African American Women Undergoing Chemotherapy for Early-Stage Breast Cancer

Novel Combination of Toll-Like Receptor (TLR)-7 Agonist Imiquimod and Local Radiation Therapy in the Treatment of Metastatic Breast Cancer Involving the Skin or Chest Wall

Combination of irinotecan and bevacizumab for heavily pretreated recur- rent ovarian cancer: A phase II trial

Minimal Acute Toxicity Associated With Concurrent Adjuvant Carboplatin and Accelerated Radiation Therapy for Triple Negative Breast Cancer

Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers

PP 66 Utility of VEGF and IL-6 as biomarkers for response to PTC299, a novel antiangiogenic

CA-125 surveillance for women with ovarian, fallopian tube or primary peritoneal cancers: What do survivors think?

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

Abstract P5-11-07: The significance of androgen receptor co-expression in ER+ metastatic breast cancer patients treated with palbociclib

Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy

Abstract P1-07-28: Retrospective analysis of clinicopathologic features predictive of oncotype DX discordance in estrogen receptor positive, node negative breast cancer patients

Abstract OT1-03-08: A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer

Abstract P1-07-16: Retrospective analysis of oncotype DX recurrence score (RS) and discordance in patients with node-negative, ER+ breast cancer with recurrence

Abstract OT1-01-10: Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer

Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial)

Phase I/II study of tandem cycles of high‐dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer

Abstract OT2-01-19: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer

Complementary and alternative medicine : The role of the cancer center

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

High-dose chemotherapy for breast cancer: evolving data

Reduction of Paclitaxel-induced Peripheral Neuropathy with Glutamine

Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer

Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer

Suchergebnisse filtern